Zicix (OTCMKTS:ZICX) Vs. Invitae (NYSE:NVTA) Head-To-Head Analysis
Zicix (OTCMKTS:ZICX) Vs. Invitae (NYSE:NVTA) Head-To-Head Analysis
Zicix (OTCMKTS:ZICX – Get Rating) and Invitae (NYSE:NVTA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.
Zicix(OTCMKTS：ZICX-GET Rating)和Invitae(NYSE：NVTA-GET Rating)都是小盘医疗公司，但哪一家是更好的投资？我们将根据这两家公司的风险、机构所有权、分析师建议、收益、盈利能力、股息和估值的强弱对它们进行比较。
Analyst Ratings
分析师评级
This is a breakdown of current ratings and recommmendations for Zicix and Invitae, as reported by MarketBeat.
据MarketBeat报道，这是对Zicix和Invitae的当前评级和推荐的细分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zicix | 0 | 0 | 0 | 0 | N/A |
| Invitae | 3 | 9 | 0 | 0 | 1.75 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Zicix | 0 | 0 | 0 | 0 | 不适用 |
| 邀请函 | 3 | 9 | 0 | 0 | 1.75 |
Invitae has a consensus price target of $8.04, suggesting a potential upside of 168.10%. Given Invitae's higher probable upside, analysts clearly believe Invitae is more favorable than Zicix.
Invitae的一致目标价为8.04美元，暗示潜在上涨168.10%。鉴于Invitae的上行可能性更高，分析师显然认为Invitae比Zicix更有利。
Volatility & Risk
波动性与风险
Earnings & Valuation
收益与估值
This table compares Zicix and Invitae's gross revenue, earnings per share and valuation.
此表比较了Zicix和Invitae的毛收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zicix | N/A | N/A | N/A | N/A | N/A |
| Invitae | $460.45 million | 1.58 | -$379.01 million | ($13.84) | -0.22 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Zicix | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
| 邀请函 | 4.6045亿美元 | 1.58 | -3.7901亿美元 | ($13.84) | -0.22 |
Zicix has higher earnings, but lower revenue than Invitae.
与Invitae相比，Zicix的收益更高，但收入更低。
Insider and Institutional Ownership
内部人与机构持股
88.3% of Invitae shares are held by institutional investors. 1.1% of Invitae shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Invitae 88.3%的股份由机构投资者持有。Invitae 1.1%的股份由内部人士持有。强大的机构持股表明，捐赠基金、大型基金管理公司和对冲基金相信，一家公司有望实现长期增长。
Profitability
盈利能力
This table compares Zicix and Invitae's net margins, return on equity and return on assets.
此表比较了Zicix和Invitae的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Zicix | N/A | N/A | N/A |
| Invitae | -617.65% | -39.04% | -17.75% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Zicix | 不适用 | 不适用 | 不适用 |
| 邀请函 | -617.65% | -39.04% | -17.75% |
Summary
摘要
Invitae beats Zicix on 5 of the 8 factors compared between the two stocks.
在比较两只股票的8个因素中，Invitae有5个胜过Zicix。
About Zicix
关于Zicix
(Get Rating)
(获取评级)
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
Zicix公司通过其子公司德克萨斯移动健康公司在德克萨斯州休斯顿提供诊断医学成像服务。它提供心脏诊断服务，包括超声心动图、压力测试、颈动脉超声以及HARTER和事件监测服务；医疗服务，如普通医疗、家庭健康患者的医疗护理、普通和移民体检、减肥、冷激光止痛治疗、物理治疗和抗衰老治疗；以及MRI、CT和X光服务。该公司前身为Bederra Corporation，并于2011年2月8日更名为Zicix Corporation。Zicix公司成立于1979年，总部设在德克萨斯州休斯顿。
About Invitae
关于Invitae
(Get Rating)
(获取评级)
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae公司是一家医学遗传学公司，将遗传信息整合到主流医学中，以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因测试，包括遗传癌、心脏病学、神经病学、儿科、肿瘤学、代谢疾病和罕见疾病；数字健康解决方案；以及健康数据服务。它为患者、医疗保健提供者、生物制药公司和其他合作伙伴提供服务。该公司前身为Locus Development，Inc.，并于2012年更名为Invitae Corporation。Invitae Corporation成立于2010年，总部位于加利福尼亚州旧金山。
Receive News & Ratings for Zicix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zicix and related companies with MarketBeat.com's FREE daily email newsletter.
接受Zicix Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Zicix和相关公司的最新新闻和分析师评级的每日简明摘要。
译文内容由第三方软件翻译。